Elliott Management Corp. Increases Stake in Swedish Match

Nov.01.2022
Elliott Management Corp. Increases Stake in Swedish Match
Elliott Management increases stake in Swedish Match prior to deadline on decision to accept Philip Morris' acquisition offer.

On October 28th, well-known investment firm Elliott Management Corp. announced its decision to increase its stake in Sweden's Match Group to over 10%. This move came just a week before the November 4th deadline for shareholders to decide whether or not to accept Philip Morris International's (PMI) acquisition offer for the Swedish company.


In May of this year, PMI offered approximately $16 billion to acquire Swedish Match. The board of directors at Swedish Match recommended that shareholders accept the offer, but some investors, including Elliott Management Corp., opposed it, stating that the offer undervalued their company.


Earlier this month, PMI increased its offer from SEK 106 per share in May to SEK 116 per share ($10.34). The board of Swedish Match recommended that shareholders accept PMI's revised offer.


According to Swedish law, PMI requires approval from 90% of its shareholders to gain full control of the company. Elliot has increased its ownership stake from 7.25% to 10.5%, meaning that if they refuse the proposal, the transaction will not be able to go through. PMI has stated that they will not increase the revised offer price any further when announcing the increased bid.


PMI has the option to lower acceptance thresholds and gain a majority stake to prevent a failed acquisition. Prior to Elliott disclosing higher ownership, CEO of Swedish Match, Lars Dahlgren, told Reuters that he believes the company can develop independently or in partnership with Philip Morris.


I believe that as an independent company, we have exciting prospects, but I see exciting opportunities for potential mergers," he said.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in translation skills, the translated article may not fully convey the intended meaning of the original. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Leather Wrap + Mini Display: DOJO’s New Product Launches in the U.S., Priced Around $15
Leather Wrap + Mini Display: DOJO’s New Product Launches in the U.S., Priced Around $15
DOJO lists Sphere S 40K in the U.S.: semi-transparent leather wrap, mini status display; 20 mL/40,000 puffs/1000 mAh, ECO/SMART; $14.99; some pages “Coming Soon.”
Oct.14 by 2FIRSTS.ai
Police in Turkey's Isparta Province Seize 29 Illegal E-Cigarettes in Special Operation, 1 Suspect Identified
Police in Turkey's Isparta Province Seize 29 Illegal E-Cigarettes in Special Operation, 1 Suspect Identified
Police in Isparta province, Türkiye, seized 29 illegal e-cigarettes and a suspect has been filed for investigation.
Sep.24 by 2FIRSTS.ai
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
HQD has listed the disposable HQD GO on its official site and U.S. channels. The device touts 35,000 puffs, three power levels with adjustable airflow, and a 30 mg/ml nicotine strength. On U.S. retail websites, it’s priced at about $29.99.
Oct.24 by 2FIRSTS.ai
Philip Morris International and Swedish Match Win Collective Lawsuit Over Zyn Nicotine Pouches
Philip Morris International and Swedish Match Win Collective Lawsuit Over Zyn Nicotine Pouches
In a recent victory, Philip Morris International and Swedish Match won a lawsuit concerning their product Zyn's pricing.
Sep.25 by 2FIRSTS.ai
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
2Firsts Feature | The “Pink Tax” in Vaping: How Women-Centric Design and Pricing Are Recasting the Competitive Landscape
Overseas e-cig brands are embracing “for her” designs, turning devices into fashion accessories. 2Firsts notes a new “pink tax” emerging through design and pricing, reflecting shifting gender and branding strategies.
Oct.20